Condition: Locally Advanced Non-Small Cell Lung Cancer · Sponsor: Sun Yat-sen University
Consolidative immunotherapy following concurrent chemoradiotherapy, based on the PACIFIC trial, has become the standard treatment for locally advanced non-small cell lung cancer (LANSCLC). Radiotherapy strategies for maximizing efficacy and local control require further investigation. This phase III, randomized controlled clinical trial is to investigate the efficacy and safety of hypofractionated chemoradiotherapy followed by consolidative immunotherapy versus conventional fractionated chemoradiotherapy followed by consolidative immunotherapy in LANSCLC patients.
This description comes directly from the study's public registry record.
Bo Qiu, Professor · 02087343031 · qiubo@sysucc.org.cn
Hui Liu, Professor · 02087343031 · liuhui@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Gansu Provincial Cancer Hospital | Lanzhou, Gansu, China | Recruiting |
| Sun yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07052669